Boston Scientific Corporation (NYSE: BSX) is a healthcare company, listed on the NYSE. Alpha Stocks Insight has published 3 articles on BSX since May 18, 2026, most recently "Boston Scientific (NYSE: BSX) Beats Q2 2026 EPS Estimates, Raises Full-Year Adjusted EPS Guidance" on Wednesday, July 29, 2026. Coverage to date spans Health Care and Earnings Report, tracking BSX's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Price
$43.96
Today
-2.22%
Mkt Cap
$65.2B
P/E
17.9x
52W High
$109.50
52W Low
$42.20
Data via Finnhub · refreshes hourly · not financial advice
BSX posted adjusted EPS of $0.86 vs. the $0.84 consensus and $5.44B in revenue, up 7.5% YoY, while lifting its full-year adjusted EPS outlook to $3.28-$3.32.
Boston Scientific's coronary lithotripsy catheter met primary safety and effectiveness endpoints in pivotal FRACTURE IDE trial, clearing a key regulatory hurdle.
Boston Scientific commits $1.5 billion investment in MiRus, a transcatheter heart valve maker, expanding its interventional cardiology portfolio.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.